W. Wuyts

UZ Leuven

Poster Author Of 5 e-Posters

 ePosters
12. Diffuse Parenchymal Lung Diseases: ILD, Sarcoidosis, IPF, LAM

A4088 - Health-Related Quality of Life in Patients with IPF Treated with Nintedanib: Stratified Analysis from the INPULSIS® Trials

Presenter:
Date
05/20/2019
Room
Room C140/C142 (Level 1), KBHCCD
Session Name
B103 - ILD: THERAPY
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
12. Diffuse Parenchymal Lung Diseases: ILD, Sarcoidosis, IPF, LAM

A4092 - Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

Presenter:
Date
05/20/2019
Room
Room C140/C142 (Level 1), KBHCCD
Session Name
B103 - ILD: THERAPY
Session Type
RAPiD: Rapid Abstract Poster Discussion Session
Authors
12. Diffuse Parenchymal Lung Diseases: ILD, Sarcoidosis, IPF, LAM

A4597 - Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-Controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2)

Presenter:
Date
05/21/2019
Room
Area H (Hall F, Level 2), KBHCCD
Session Name
C34 - ILD AND IPF: CLINICAL AND MECHANISTIC STUDIES
Session Type
Thematic Poster Session
Authors
12. Diffuse Parenchymal Lung Diseases: ILD, Sarcoidosis, IPF, LAM

A5265 - Epigenetic Age Acceleration in Idiopathic Pulmonary Fibrosis

Presenter:
Date
05/21/2019
Room
Area C (Hall F, Level 2), KBHCCD
Session Name
C59 - GENETIC AND EPIGENETIC MECHANISMS IN PULMONARY FIBROSIS
Session Type
Thematic Poster Session
Authors
12. Diffuse Parenchymal Lung Diseases: ILD, Sarcoidosis, IPF, LAM

A5625 - Consistent Effect of Nintedanib in Patients with IPF and Degrees of Impairment in Gas Exchange

Presenter:
Date
05/21/2019
Room
Room C140/C142 (Level 1), KBHCCD
Session Name
C101 - NON-IDIOPATHIC INTERSTITIAL PNEUMONIA NATURAL HISTORY AND PROGNOSIS AND ILD THERAPY
Session Type
Poster Discussion Session
Authors